JEMPERLI

GlaxoSmithKline Inc🇨🇦 Health Canada

Approval Id: 192870aea00d0647
Drug Approval Canada Name: JEMPERLI
Product Name: JEMPERLI
Status: Marketed
Status Date: 2022-02-22
Original Market Date: 2022-02-22
Din: 02523434
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravenous
Schedule: Schedule D , Prescription
Ahfs: 10:00.00
Atc Original: L01FF07 DOSTARLIMAB
Atc Name: l 01 ff 07
Aig Number: 0163298001
Company Name: GlaxoSmithKline Inc
Company Address: 800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path: /organization/glaxosmithkline-inc

DOSTARLIMAB

50 MG / ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

192870aea00d0647

Type

Standard